Lundbeck Q3 2019 Financial Results

Balance sheet is strong with limited debt and strong operating cash flow Assets (DKKbn) Liabilities (DKKbn) 48 Cash & cash equivalents: Declines following the acquisition of Abide, 23,0 23,5 23,0 23,5 increased dividend pay-out and payment of DoJ settlement 8,0 Working capital: Declines DKK Intangible assets 10,0 1.1bn as short term payables Equity 14,3 14,4 decline (eg. Doj payment) Property, 2,0 Plant & 1,3 equipment 2,5 Interest-bearing debt: Higher due to recognition of lease liabilities cf. 1,8 Financial 1,2 assets IFRS 16 1,7 3,3 Inventories 1,6 Provisions 1,7 0,1 Debt 0,7 3,6 Acquisition of Alder BioPharmaceuticals will increase leverage Receivables 6,6 Cash & cash equivalents 7,1 Payables 6,7 4,5 31 Dec. 2018 30 Sep. 2019 31 Dec. 2018 30 Sep. 2019 Lundbeck

View entire presentation